featured
Chemotherapy and Targeted Therapy for Patients With Endocrine-Pretreated or HR− HER2− Metastatic Breast Cancer: ASCO Guideline Update
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update
J. Clin. Oncol 2021 Jul 29;[EPub Ahead of Print], B Moy, RB Rumble, SE Come, NE Davidson, A Di Leo, JR Gralow, GN Hortobagyi, D Yee, IE Smith, M Chavez-MacGregor, R Nanda, HL McArthur, L Spring, KE Reeder-Hayes, KJ Ruddy, PS Unger, S Vinayak, WJ Irvin, A Armaghani, MA Danso, N Dickson, SS Turner, CL Perkins, LA CareyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.